News

UK scientists are aligning human and lab experiments in researching the potential of magic mushrooms to boost the effects of talking therapies to ease depression in people who are dealing with end-of-life diagnoses.

The pre-clinical laboratory studies will be carried out by the team at Kent-headquartered contract research organisation (CRO) Transpharmation, in partnership with human clinical trials led by London-based specialist psychedelic clinical research organisation Clerkenwell Health.

Read more ...

“Comorbidity of chronic pain and mood disorders: breaking the vicious cycle” This is the aim of HaPpY and we are thrilled to have been invited to join as well-known experts in this therapeutic area. HaPpY has assembled a world-class team of behavioural neuroscientists, electrophysiologists, molecular biologists, neuropharmacologists and clinicians specialising in pain and/or mood disorders from academic research labs and hospitals along with experts of the non-academic sector specialising in new instrumentation and technology, drug development and scientific promotion and communication. We can’t wait to get started. For details of all our pain and mood disorders preclinical areas please see our pain pages https://www.transpharmation.co.uk/services/

CEO Mark Duxon will take part in the next OBN Digital Event: ‘Building an Innovative Life Sciences Company' kindly hosted by Discovery Park - Sandwich, Kent, UK on Wednesday 12 May BST 1pm-2pm.

Tickets are complimentary for OBN Members and Discovery Park Associates, with a nominal fee of £25+VAT for Non-Members - simply click here for all the details and to book http://ow.ly/YZT750ErJsk.

As an entrepreneur, working to turn your innovation into reality can be hugely challenging, with many unexpected twists and turns along the way. However a great deal can be learnt from fellow entrepreneurs, including how to identify and make the most of opportunities and using challenges to further strengthen your growing business. 

We hope that you can join us for this event when you will hear first-hand from founders of four companies based at Discovery Park, who will share insight into the key challenges they have faced and overcome, along with key learnings they would pass on to fellow founders and business leaders. 

Please do invest one hour of your time, come and be inspired.

Transpharmation’s CEO Mark Duxon was pleased to speak with Guy Martin of The Pharma Letter about the impact of #Brexit on CROs. We have opened our fourth lab, most recently in Poland, and now with a footprint in the UK and continental Europe we are able to extend our services and partnerships to mitigate against border pressures, optimising opportunities for innovation and exciting collaborations.

Read the full interview here

The creation of Transpharmation Poland will also create new jobs and new career options. In the first instance, Transpharmation is seeking a senior scientist and a research assistant, establishing the laboratory as its primary centre for neuropsychiatric disorders. If you have a background in preclinical neuroscience, are eligible to work in Poland and would like to be a part of this significant new venture please contact Dr. Ewa Sokolowska This email address is being protected from spambots. You need JavaScript enabled to view it.

Senior Scientist / Scientist

Technician Research Assistance

Transpharmation announces the opening of a new laboratory in Poland. “We see Poland rising within the biotechnology and drug-discovery sector, with pharmaceutical companies moving and expanding to develop new technologies and focus on novel treatments to tackle neurodegenerative, neuropsychiatric and neurodevelopmental diseases which affect us all,” reveals Mark Duxon CEO. This news comes not long after Transpharmation revealed the launch of additional laboratory space at Discovery Park, Kent, boosting its growing list of facilities and opening up further opportunities to expand its preclinical services.

Read the full press release here

Frontiers in Psychiatry have just published a peer review journal by the Transpharmation Ireland team, led by Jack Prenderville. ‘The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.’ Major depressive disorder, (MDD) is the leading cause of disability worldwide. The majority of antidepressant drugs require several weeks or months of treatment to demonstrate efficacy and a subset of patients are resistant to such interventions. In this publication we examine depressive-like behavioural phenotypes in the Wistar-Kyoto rat model of depression, establish and demonstrate an effective clinically relevant dose of the novel therapeutic agent ketamine. To read the full publication please head to https://www.frontiersin.org/articles/10.3389/fpsyt.2020.599588/full

Recognised by drug developers world-wide, Transpharmation’s client base continues to grow. With the expansion of therapeutic indications offered, the move to new, state of the art research facilities at Discovery Park in Kent is perfectly timed to hit the ground running from January 2021. With a vast array of laboratory and office space, managed by the hugely experienced company Agenda Life Sciences, Transpharmation’s scientists will have everything they need in place to deliver scientific excellence, remaining focussed on the important drug discovery work we carry out for our clients. 

Discovery Park, home to many specialist research companies, was recently named a Life Sciences Opportunity Zone by the UK Government’s Offices for Life Sciences. This multi-million pound site is known for its heritage of scientific excellence and delivery of new treatments for patients. With strong transport links to
airports, trains and ports it is ideally positioned for Transpharmation’s growing global customer portfolio.

Whilst Transpharmation will retain their facilities at The London Bioscience Innovation Centre, Royal Veterinary College and Trinity College Institute of Neuroscience, Dublin, the move to Discovery Park, on their 10th year anniversary, is a pivotal point in the company’s history and sets the agenda for their future growth.

Official press release

Ten years has gone by so quickly. When the company started, we limited ourselves to the study of pain and cognition. Now we offer specialist bespoke studies across multiple therapeutic indications including pain, depression, schizophrenia, epilepsy and neurodegeneration to clients all around the world. Science will always remain our passion, along with the drive to research and deliver life-changing medicines. Thank you very much for your support along the way, we hope to work with you for many years to come.

Transpharmation’s scientific team presented five posters at the recent SfN conference and interest in them was high. We’ve made all five available to view or download here on our website; simply complete a short application process by following this link - Register

Transpharmation Ltd are a global CRO, wherever you are, whatever language you speak, we’d be happy to work with you. If you have a project in mind, or simply wish to find out how we might be able to help you during 2020, please contact me at This email address is being protected from spambots. You need JavaScript enabled to view it. We have clients already scheduling work with us next year.

On Monday 9th December, Transpharmation’s scientific expert Dr Sandor Kantor will be presenting his work on ''Altered EEG oscillations as correlates of abnormal brain function in neuropsychiatric diseases'' as part of the Trinity College Institute of Neuroscience Seminar Series 2019. For further information please contact our Dublin based science lead Jack Prenderville This email address is being protected from spambots. You need JavaScript enabled to view it.

A focus on sleep, depression and chemobrain in collaboration with the University of Hertfordshire.

For patients suffering with chronic neuropathic pain, (e.g. diabetes, chemotherapy) the need for suitable novel therapies is imperative. The key to developing new treatments lies in identifying measurable endpoints in both preclinical and human subjects to aid translation of preclinical results to the clinic.

Building on the impressive work that Transpharmation’s Dr Amy Fisher has already accomplished, we have partnered with Dr Lisa Lione's team at the University of Hertfordshire to successfully recruit multi award winning PhD student Michael Lanigan to focus exclusively on refining novel endpoints for our neuropathic pain assays. Michael was recently awarded the prestigious 2019 British Pharmacological Society Undergraduate Prize.

Using our strengths in EEG, MMN, cognition and biomarker analysis we will be working with UoH to better understand the behavioural and biochemical impact of pain and analgesia. We hope this work will create better translational preclinical research models, refine the drug discovery process for our clients and lead to the development of new medicines for patients suffering with neuropathic pain. If you would like to see our recent research in this area, please use this link to view the posters here View Posters

We are delighted to announce that Transpharmation Ltd is to be one of the partners enlisted in the EU-funded first international project to study dystrophin in the brain in Duchenne and Becker Muscular Dystrophy (DMD and BMD).

Read more ...

Pharma Tech Outlook magazine have named Transpharmation ‘company of the year’ in their ‘top 5 UK CRO’s’ feature. We’re proud of this achievement on behalf of all the clients that we’ve worked with over the years and it’s a great start to our 10th anniversary year.

Read more ...